Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 7
2016 42
2017 60
2018 97
2019 99
2020 108
2021 116
2022 79
2023 79
2024 62
2025 74
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

742 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean elpatasvir antiviral (533,794 results)?
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB, Kelley D, Childs-Kean LM. Chahine EB, et al. Ann Pharmacother. 2018 Apr;52(4):352-363. doi: 10.1177/1060028017741508. Epub 2017 Nov 8. Ann Pharmacother. 2018. PMID: 29115151 Review.
POLARIS-2 failed to demonstrate that sofosbuvir/velpatasvir/voxilaprevir for 8 weeks was noninferior to sofosbuvir/velpatasvir for 12 weeks in patients with HCV genotype 1 through 6 who had no prior exposure to direct-acting antivirals (DAAs). ...POLARIS-4 de …
POLARIS-2 failed to demonstrate that sofosbuvir/velpatasvir/voxilaprevir for 8 weeks was noninferior to sofosbuvir/velpatasvir …
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB, Sucher AJ, Hemstreet BA. Chahine EB, et al. Ann Pharmacother. 2017 Jan;51(1):44-53. doi: 10.1177/1060028016668897. Epub 2016 Oct 1. Ann Pharmacother. 2017. PMID: 27609942 Review.
OBJECTIVES: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection. DATA SOURCES: A literature search through PubMed was conducted (June 2008 to August 2016) using the terms GS-5816, …
OBJECTIVES: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C …
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P, Tiong KLA, Neo JE, Mohan BP, Wijarnpreecha K, Tam YCS, Coppola N, Preda CM, Wong YJ. Devan P, et al. Viruses. 2023 Jun 30;15(7):1489. doi: 10.3390/v15071489. Viruses. 2023. PMID: 37515176 Free PMC article.
About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in DAA-experienced CHC patients rem …
About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global …
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Da BL, Lourdusamy V, Kushner T, Dieterich D, Saberi B. Da BL, et al. Eur J Gastroenterol Hepatol. 2021 Jun 1;33(6):859-861. doi: 10.1097/MEG.0000000000001786. Eur J Gastroenterol Hepatol. 2021. PMID: 32541241
AIMS: Report the real-world experience of the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C virus (HCV) infected patients who have previously experienced a direct-acting antiviral (DAA) containing regimen. ...
AIMS: Report the real-world experience of the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hep …
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS, Shahoumian TA, Loomis TP, Backus LI. Belperio PS, et al. J Viral Hepat. 2019 Aug;26(8):980-990. doi: 10.1111/jvh.13115. Epub 2019 May 10. J Viral Hepat. 2019. PMID: 31012179
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting antiviral (DAA)-experienced patients. ...
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting …
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Heo YA, Deeks ED. Heo YA, et al. Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5. Drugs. 2018. PMID: 29546556 Review.
In the phase III POLARIS trials, in patients who had HCV genotype 1-6 infection with or without compensated cirrhosis, overall rates of sustained virological response at 12 weeks post-treatment (SVR(12)) with sofosbuvir/velpatasvir/voxilaprevir were high after 8 weeks of t …
In the phase III POLARIS trials, in patients who had HCV genotype 1-6 infection with or without compensated cirrhosis, overall rates of sust …
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.
Ren XD, Fu X, He YQ, Li CY, Guo M, Qiao M. Ren XD, et al. Medicine (Baltimore). 2022 Oct 21;101(42):e31183. doi: 10.1097/MD.0000000000031183. Medicine (Baltimore). 2022. PMID: 36281168 Free PMC article.
INTRODUCTION: The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). ...CONCLUSION: In conclusion, the 12-week regimen of sofosbuvir-velpatasvir was highly effective in HCV patients. Except for genoty …
INTRODUCTION: The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV) …
Mixed Essential Cryoglobulinemia.
Sankhyan P, Gonzalez-Estrada A. Sankhyan P, et al. Mayo Clin Proc. 2017 May;92(5):854. doi: 10.1016/j.mayocp.2017.02.010. Mayo Clin Proc. 2017. PMID: 28473046 No abstract available.
742 results